Microswitch-Guided Sampling for the Detection of Ligand Signaling Bias in GPCR Systems
- 1University of Warsaw
Abstract
Biased signaling occurs when a ligand preferentially activates a specific signaling pathway at a certain receptor within a particular cellular environment. As pharmaceuticals, functionally selective (biased) compounds can engage beneficial signaling pathways while avoiding those linked to adverse effects, resulting in safer and targeted therapeutics. However, existing experimental methods for characterizing ligand bias are often time-consuming and costly, and they hardly elucidate the structural basis of biased signaling. Here, we present microswitch-guided sampling (MGS), a computational method that uses conformational changes in molecular switches to assess ligand bias in G protein-coupled receptor systems. Using initial 2 s all-atom molecular dynamics simulations of the {beta}1-adrenergic receptor ({beta}1AR), the chemokine receptor CXCR3, and the -opioid receptor (OR) in complex with either G protein or {beta}-arrestin and known biased ligands, we identified microswitches whose conformational changes were linked to activation of a specific signaling pathway. We then sampled simulation trajectories for representative complex conformations selected at these microswitch-change time points and used them as starting points for 500 ns ligand-swapped simulations, in which we exchanged biased ligands between complexes. We observed clear differences in conformational changes between complexes bound to pathway-activating and non-activating ligands in at least two of three replicas across all examined systems, demonstrating that MGS can distinguish G protein-biased from {beta}-arrestin-biased ligands. These findings show that MGS is an effective tool for assessing signaling pathway bias in GPCR systems and suggest that this methodology can be applied to other GPCR targets to act as a fast, ns-scale computational assay to detect functional selectivity with molecular dynamics.
Related
- Sampling composition and sequencing effort in the detection of within-hospital Gram-negative genomic clustering: a prospective observational study at two tertiary-care hospitals
- Ambrisentan ameliorates methotrexate nephrotoxicity through modulation of RhoA/ROCK and PI3K/MDM2-associated signaling: network pharmacology-guided discovery and in vivo confirmation
- Multimodal deep learning with particle swarm guided feature refinement for automated pain detection
- Concordance Study on Molecular Detection of Thyroid Nodules by Ultrasound Guided Fine Needle Aspiration
- Determinants of delayed detection and reporting of epidemic-prone diseases in Sub-Saharan Africa: a systematic review and CFIR-guided synthesis.
BibTeX
@misc{dragan2026microswitchguided,
title = {{Microswitch-Guided Sampling for the Detection of Ligand Signaling Bias in GPCR Systems}},
author = {P. Dragan and D. Latek},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.16.752090},
url = {https://www.biorxiv.org/content/10.64898/2026.09.16.752090v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Microswitch-Guided Sampling for the Detection of Ligand Signaling Bias in GPCR Systems
AU - P. Dragan
AU - D. Latek
PY - 2026
DA - 2026/09/16
PB - bioRxiv
DO - 10.64898/2026.09.16.752090
UR - https://www.biorxiv.org/content/10.64898/2026.09.16.752090v1
AB - Biased signaling occurs when a ligand preferentially activates a specific signaling pathway at a certain receptor within a particular cellular environment. As pharmaceuticals, functionally selective (biased) compounds can engage beneficial signaling pathways while avoiding those linked to adverse effects, resulting in safer and targeted therapeutics. However, existing experimental methods for characterizing ligand bias are often time-consuming and costly, and they hardly elucidate the structural basis of biased signaling. Here, we present microswitch-guided sampling (MGS), a computational method that uses conformational changes in molecular switches to assess ligand bias in G protein-coupled receptor systems. Using initial 2 s all-atom molecular dynamics simulations of the {beta}1-adrenergic receptor ({beta}1AR), the chemokine receptor CXCR3, and the -opioid receptor (OR) in complex with either G protein or {beta}-arrestin and known biased ligands, we identified microswitches whose conformational changes were linked to activation of a specific signaling pathway. We then sampled simulation trajectories for representative complex conformations selected at these microswitch-change time points and used them as starting points for 500 ns ligand-swapped simulations, in which we exchanged biased ligands between complexes. We observed clear differences in conformational changes between complexes bound to pathway-activating and non-activating ligands in at least two of three replicas across all examined systems, demonstrating that MGS can distinguish G protein-biased from {beta}-arrestin-biased ligands. These findings show that MGS is an effective tool for assessing signaling pathway bias in GPCR systems and suggest that this methodology can be applied to other GPCR targets to act as a fast, ns-scale computational assay to detect functional selectivity with molecular dynamics.
ER -